HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
ANAB
AnaptysBio Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $1.68B
Market Cap
$1.68B
Enterprise Val
$1.67B
P/E Ratio
-62.75
P/B Ratio
131.87
Trailing PEG (1Y)
-1.43
As Of
Aug 13, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$12.7M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity442.91%
Return on Assets-7.75%
Current Ratio7.58
Debt/Equity21.76
LT Debt/Equity21.59
Revenue Per Share0.89

Income Statement

Mar 31, 2026
Revenue$25.6M
Cost of Revenue$0.00
Gross Profit$25.6M
R&D$34.0M
SG&A$26.2M
Operating Expenses$60.2M
Operating Income-$34.6M
Interest Expense$0.00
Tax Expense$40.0K
Net Income-$52.9M
EPS (Basic)$-1.84
EPS (Diluted)$-1.84
EBIT-$52.8M
EBITDA-$52.2M
Consolidated Income-$52.9M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$248.5M
Accounts Receivable$25.7M
Inventory$0.00
Current Assets$316.1M
LT Investments$0.00
Property, Plant & Equipment$13.3M
Intangibles$0.00
Non-Current Assets$13.6M
Total Assets$329.7M
Accounts Payable$7.5M
Current Debt$2.1M
Current Liabilities$41.7M
LT Debt$275.2M
Non-Current Liabilities$275.2M
Total Liabilities$316.9M
Total Debt$277.4M
Retained Earnings-$825.4M
Shareholder Equity$12.7M
Shares Outstanding28,748,255

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$25.9M
Investing Cash Flow$35.0M
Financing Cash Flow$1.2M
CapEx-$17.0K
Free Cash Flow-$25.9M
Depreciation & Amort.$610.0K
Stock-Based Comp$14.2M
Acquisitions / Disposals$0.00
Investment Activity$35.0M
Debt Issued/Repaid-$12.8M
Equity Issued/Repaid$14.0M
Dividends Paid$0.00
Net Change in Cash$10.3M
Data cached · Meta live · Daily live · Statements live · TTL 24h